SCHEMBL1886897

SCHEMBL1886897

COc1cccc2cc(CO)c(-c3ccccc3)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.46
KDM4E B2RXH2 5/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
TOP2A P11388 2/20 0.43
TOP2B Q02880 2/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
ACACA Q13085 2/20 0.42
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HPGD P15428 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4181048 0.87 PDE4B (0.43) PDE10APDE3BPDE3APDE4APDE4B
SCHEMBL1887862 0.81 MEN1 (0.48) PDE10AKDM4EPDE3BPDE3AALDH1A1
SCHEMBL1889250 0.80 MEN1 (0.43) KDM4EACACAALDH1A1MEN1KMT2A
SCHEMBL7117069 0.80 PDE10A (0.54) PDE10AKDM4ELMNASMN1; SMN2PDE3B
SCHEMBL1880602 0.78 DHODH (0.46) KDM4EALDH1A1MEN1KMT2ACYP1A2
SCHEMBL1886039 0.78 KDM4E (0.51) KDM4EPDE3BPDE3ATOP2ATOP2B
SCHEMBL4173906 0.77 PIK3CD (0.58) KDM4ELMNASMN1; SMN2ALDH1A1HPGD
SCHEMBL19618107 0.76 PDE3B (0.41) PDE10AKDM4EPDE3BPDE3ATOP2A
SCHEMBL12970279 0.76 TOP2A (0.44) LMNAPDE3BPDE3ATOP2ATOP2B
SCHEMBL1880472 0.75 ALDH1A1 (0.40) KDM4ELMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE PDE10A 2028/4885KDM4E 2230/4885LMNA 4352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.